US equities |
MU $896.07 ▼-0.98% SPCX $147.79 ▼-0.11% NVDA $216.47 ▼-0.29% AAPL $339.50 ▼-1.00% TSLA $373.71 ▲+1.54% META $694.25 ▼-1.59% AMZN $262.63 ▲+0.07% SNDK $1,365.38 ▼-0.42%
FinancialContent

Articles published by Moderna, Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna to Present at Upcoming Conferences in September 2026
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Appoints Michael McDonnell to Board of Directors
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Science Day Highlights Expanding Potential of mRNA Platform
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna to Host Investor Event - Science Day
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
From Moderna, Inc.
Via ACCESS Newswire
Tickers MRNA
News headline image
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Tickers MRNA
News headline image
Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
From Moderna, Inc.
Via AccessWire
Tickers MRNA
News headline image
Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement
From Moderna, Inc.
Via AccessWire
Tickers MRNA
< Previous 1 2 3 4 5 6 Next >